Targeting BRAF for patients with melanoma

H. T. Arkenau*, R. Kefford, G. V. Long

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

109 Citations (Scopus)

Abstract

The prognosis of patients with metastatic melanoma is poor and not influenced by systemic therapy with cytotoxic drugs. New targeted agents directed against the RAS-RAF-MEK-ERK pathway show promising activity in early clinical development and particular interest is focused on selective inhibitors of mutant BRAF, which is present in one half of the cases of metastatic melanoma. The majority of patients on early trials of these drugs develop secondary resistance and subsequent disease progression and it is, therefore, critical to understand the underlying escape mechanisms leading to resistance.

Original languageEnglish
Pages (from-to)392-398
Number of pages7
JournalBritish Journal of Cancer
Volume104
Issue number3
DOIs
Publication statusPublished - 1 Feb 2011
Externally publishedYes

Fingerprint

Dive into the research topics of 'Targeting BRAF for patients with melanoma'. Together they form a unique fingerprint.

Cite this